Decreased Platelet Reactivity in Blood Anticoagulated with Bivalirudin or Enoxaparin Compared with Unfractionated Heparin: Implications for Coronary Intervention

[1]  C. Eika.  Inhibition of thrombin induced aggregation of human platelets by heparin. , 2009, Scandinavian journal of haematology.

[2]  B. Sobel,et al.  Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  B. Sobel,et al.  Platelet Reactivity in Coronary Ostial Blood: A Reflection of the Thrombotic State Accompanying Plaque Rupture and of the Adequacy of Anti-Thrombotic Therapy , 2001, Journal of Thrombosis and Thrombolysis.

[4]  B. Sobel,et al.  Platelet Reactivity Characterized Prospectively: A Determinant of Outcome 90 Days After Percutaneous Coronary Intervention , 2001, Circulation.

[5]  B. Sobel,et al.  Time and Dose Dependent Augmentation of Inhibitory Effects of Abciximab by Aspirin , 2001, Thrombosis and Haemostasis.

[6]  C. Cannon,et al.  Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. , 2000, The American journal of cardiology.

[7]  B. Sobel,et al.  Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. , 1999, Thrombosis research.

[8]  B E Sobel,et al.  Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. , 1999, The American journal of cardiology.

[9]  B. Sobel,et al.  The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. , 1999, The American journal of cardiology.

[10]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[11]  K. Mann,et al.  Differential effects of anticoagulants on the activation of platelets ex vivo. , 1997, Circulation.

[12]  K. Mann,et al.  Blood clotting in minimally altered whole blood. , 1996, Blood.

[13]  M. Frojmovic,et al.  Optimally functional fluorescein isothiocyanate‐labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation , 1996, British journal of haematology.

[14]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[15]  R. Schwartz,et al.  Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. , 1994, Circulation.

[16]  E. Topol,et al.  Use of A Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplast , 1993, Circulation.

[17]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[18]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[19]  C. Forbes,et al.  The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. , 1973, Clinical science and molecular medicine.

[20]  Samer S. Kabbani MD,et al.  Platelet Reactivity in Coronary Ostial Blood: A Reflection of the Thrombotic State Accompanying Plaque Rupture and of the Adequacy of Anti-Thrombotic Therapy , 2001 .

[21]  R. Rosenberg,et al.  Effect of heparin and heparin fractions on platelet aggregation. , 1980, The Journal of clinical investigation.